Targeting SLFN5 may serve as a promising approach for the treatment of drug-resistant glioblastoma and/or the elimination of glioma cancer stem cells, but further research is needed to explore its feasibility and effectiveness (49). This evidence concerns the gene SLFN5 and glioblastoma.